New Repurposed Rolapitant in Nanovesicular Systems for Lung Cancer Treatment: Development, In Vitro Assessment and In Vivo Biodistribution Study

Scientists evaluated in vitro drug release, in vitro cytotoxicity on A549 lung cancer cells, nebulization performance using next generation impactor, and the in vivo biodistribution behavior.
[European Journal of Pharmaceutical Sciences]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Antineoplastic Effects of Erufosine on Small Cell and Non-Small Cell Lung Cancer Cells through Induction of Apoptosis and Cell Cycle Arrest

The effects of ErPC3 in NSCLC cell line A549 and SCLC cell line DMS 114 in terms of cell viability, induction of apoptosis, cell cycle phase distribution, gene and protein expression levels, and migration capacity were investigated. 25 µM ErPC3 exhibited dose-dependent cytotoxicity against in both cancer cells.
[Molecular Biology Reports]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

The Circ-PITX1 Promotes Non-small Cell Lung Cancer Development via the miR-30e-5p/ITGA6 Axis

Gain- and loss- of function assay verified the impact of circ-PITX1 and miR-30e-5p on the proliferation, invasion, and migration of NSCLC cells.
[Cell Cycle]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Involvement of m6A Regulatory Factor IGF2BP1 in Malignant Transformation of Human Bronchial Epithelial Beas-2B Cells Induced by Tobacco Carcinogen NNK

Scientists performed colony formation assays, soft-agar assays, and tumor growth in nude mice to show that 100 mg/L Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) facilitated the malignant transformation of human bronchial epithelial Beas-2B cells.
[Toxicology and Applied Pharmacology]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Merck’s KEYTRUDA® (Pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

Merck announced that the Phase III KEYNOTE-091 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.
[Merck]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (Nivolumab) for Treatment of Solid Tumors

BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla’s two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb’s anti-PD-1 therapy nivolumab.
[BioAtla, Inc. (PR Newswire, Inc.)]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Neurokinin-1 Receptor Promotes Non-Small Cell Lung Cancer Progression through Transactivation of EGFR

Researchers identified neurokinin-1 as a significantly upregulated GPCR in the transcriptome and tissue array of human lung cancer samples, associated with advanced clinical stages and poor prognosis.
[Cell Death & Disease]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

FBI-1 Inhibits Epithelial-to-Mesenchymal Transition, Migration, and Invasion in Lung Adenocarcinoma A549 Cells by Downregulating Transforming Growth Factor-β1 Signaling Pathway

To investigate the function of factor binding inducer of short transcripts-1 (FBI-1) in epithelial-to-mesenchymal transition (EMT) in lung cancer, EMT was measured in FBI-1-deficient or FBI-1-overexpressing cells.
[Journal of Cellular Biochemistry]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

First-Line Immunotherapy for Non–Small-Cell Lung Cancer

The authors report the current status of first-line immunotherapy in metastatic non–small cell lung cance together with current challenges in selecting the best immunotherapeutic approach for the individual patient.
[Journal of Clinical Oncology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Anti-PD-L1/TGF-βR Fusion Protein (SHR-1701) Overcomes Disrupted Lymphocyte Recovery-Induced Resistance to PD-1/PD-L1 Inhibitors in Lung Cancer

Murine CMT167 lung cancer cells were engineered to express the firefly luciferase gene and implanted orthotopically in the lung of syngeneic mice. Bioluminescence imaging, flow cytometry, and immunohistochemistry were employed to determine response to immunotherapy and function of tumor-infiltrating immune cells.
[Cancer Communications]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Genprex Receives US FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination with Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. announced that the FDA has granted Fast Track Designation for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer whose disease progressed after treatment with Keytruda.
[Genprex, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share